{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:58:26Z","timestamp":1792673906403,"version":"4.5.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T00:00:00Z","timestamp":1292889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0015257","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T19:27:26Z","timestamp":1292959646000},"page":"e15257","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":82,"title":["Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model"],"prefix":"10.1371","volume":"5","author":[{"given":"C. Preston","family":"Neff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ndolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Habu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Akkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine.","volume":"455","author":"DH Barouch","year":"2008","journal-title":"Nature"},{"key":"ref2","article-title":"Report on the Global AIDS epidemic.","year":"2008"},{"key":"ref3","article-title":"New data on male circumcision and HIV prevention: policy and programme implications.","year":"2007"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tips.2009.10.009","article-title":"Oral pre-exposure prophylaxis for HIV prevention.","volume":"31","author":"JG Garcia-Lerma","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa0801941","article-title":"Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.","volume":"359","author":"NI Kumwenda","year":"2008","journal-title":"N Engl J Med"},{"key":"ref6","first-page":"CD003510","article-title":"Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.","author":"J Volmink","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.01367-07","article-title":"Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.","volume":"52","author":"ME Polhemus","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1371\/journal.pone.0000875","article-title":"Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.","volume":"2","author":"UL Abbas","year":"2007","journal-title":"PLoS One"},{"key":"ref9","article-title":"Antiretroviral drugs used in the treatment of HIV infection.","year":"2009"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic.","volume":"85","author":"S Broder","year":"2010","journal-title":"Antiviral Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1086\/507306","article-title":"Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.","volume":"194","author":"S Subbarao","year":"2006","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.qai.0000224972.60339.7c","article-title":"Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.","volume":"43","author":"KK Van Rompay","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.","volume":"5","author":"JG Garcia-Lerma","year":"2008","journal-title":"PLoS Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11904-009-0003-2","article-title":"Novel humanized murine models for HIV research.","volume":"6","author":"PW Denton","year":"2009","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-4690-6-76","article-title":"The utilization of humanized mouse models for the study of human retroviral infections.","volume":"6","author":"R Van Duyne","year":"2009","journal-title":"Retrovirology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI0213236","article-title":"Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent.","volume":"109","author":"KV Khanna","year":"2002","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1097\/00002030-200111230-00003","article-title":"Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides.","volume":"15","author":"S Di Fabio","year":"2001","journal-title":"Aids"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/00002030-200307250-00003","article-title":"Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation.","volume":"17","author":"S Di Fabio","year":"2003","journal-title":"Aids"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0897.2007.00478.x","article-title":"Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1.","volume":"57","author":"OJ D'Cruz","year":"2007","journal-title":"Am J Reprod Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.chom.2009.06.006","article-title":"Humanized mice for modeling human infectious disease: challenges, progress, and outlook.","volume":"6","author":"N Legrand","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri2017","article-title":"Humanized mice in translational biomedical research.","volume":"7","author":"LD Shultz","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1093933","article-title":"Development of a human adaptive immune system in cord blood cell-transplanted mice.","volume":"304","author":"E Traggiai","year":"2004","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.","volume":"12","author":"MW Melkus","year":"2006","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CVI.00403-06","article-title":"Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection.","volume":"14","author":"DS An","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"15951","DOI":"10.1073\/pnas.0604493103","article-title":"Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2\u2212\/\u2212gamma c\u2212\/\u2212 mice.","volume":"103","author":"S Baenziger","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-4690-3-76","article-title":"HIV-1 infection and CD4 T cell depletion in the humanized Rag2\u2212\/\u2212gamma c\u2212\/\u2212 (RAG-hu) mouse model.","volume":"3","author":"BK Berges","year":"2006","journal-title":"Retrovirology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1128\/JVI.02010-06","article-title":"Human immunodeficiency virus type 1 pathobiology studied in humanized BALB\/c-Rag2\u2212\/\u2212gammac\u2212\/\u2212 mice.","volume":"81","author":"S Gorantla","year":"2007","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2006-04-017681","article-title":"Hematopoietic stem cell-engrafted NOD\/SCID\/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses.","volume":"109","author":"S Watanabe","year":"2007","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood-2006-07-033159","article-title":"HIV-1 infection and pathogenesis in a novel humanized mouse model.","volume":"109","author":"L Zhang","year":"2007","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.virol.2007.11.020","article-title":"Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2\u2212\/\u2212 gammac \u2212\/\u2212 (RAG-hu) mice.","volume":"373","author":"BK Berges","year":"2008","journal-title":"Virology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1371\/journal.pmed.0050016","article-title":"Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.","volume":"5","author":"PW Denton","year":"2008","journal-title":"PLoS Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e8829","DOI":"10.1371\/journal.pone.0008829","article-title":"Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.","volume":"5","author":"PW Denton","year":"2010","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"B Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited.","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"Faseb J"},{"key":"ref35","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.","volume":"50","author":"EJ Freireich","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.virol.2009.10.034","article-title":"Humanized Rag2(\u2212\/\u2212)gammac(\u2212\/\u2212) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year.","volume":"397","author":"BK Berges","year":"2010","journal-title":"Virology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.","volume":"47","author":"RD MacArthur","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.","volume":"30","author":"SS Lieberman-Blum","year":"2008","journal-title":"Clin Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14656561003801081","article-title":"Treatment of HIV infection with the CCR5 antagonist maraviroc.","volume":"11","author":"W Kromdijk","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1086\/655661","article-title":"Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.","volume":"202","author":"RS Veazey","year":"2010","journal-title":"J Infect Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.","volume":"287","author":"DJ Hazuda","year":"2000","journal-title":"Science"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1097\/00002030-199809000-00001","article-title":"Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.","volume":"12","author":"KK Van Rompay","year":"1998","journal-title":"Aids"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.","volume":"270","author":"CC Tsai","year":"1995","journal-title":"Science"},{"key":"ref44","article-title":"Clinicaltrials.gov FEM-PrEP(Truvada): Study to Assess the Role of Truvada in Preventing HIV Acquisition in Women."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature04055","article-title":"Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.","volume":"438","author":"RS Veazey","year":"2005","journal-title":"Nature"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0015257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T22:06:07Z","timestamp":1592172367000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0015257"}},"subtitle":[],"editor":[{"given":"Fatah","family":"Kashanchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,21]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0015257","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,21]]}}}